Wegovy Now Available Through Hims & Hers at $599 Monthly Bundle
Rhea-AI Summary
Novo Nordisk and Hims & Hers have announced a groundbreaking collaboration to make obesity care more accessible and affordable in the United States. The partnership's first initiative introduces Wegovy through the Hims & Hers platform, bundled with comprehensive healthcare services.
The offering, priced at $599 per month, includes:
- All dose strengths of Wegovy
- 24/7 care access
- Ongoing clinical support
- Nutrition guidance
- Hims & Hers membership
Patients can now access NovoCare Pharmacy directly through the Hims & Hers platform. This collaboration combines Novo Nordisk's innovative treatments with Hims & Hers' scalable healthcare delivery system. The partnership aims to improve long-term outcomes for people living with obesity while maintaining affordability. The platform will continue offering additional weight loss solutions, including oral medications, protein supplements, nutrition kits, and clinically-backed care plans.
Positive
- Strategic partnership with Novo Nordisk provides access to high-demand Wegovy medication
- New bundled offering at $599/month creates additional revenue stream
- Direct integration with NovoCare Pharmacy streamlines distribution
- Expansion of weight loss solutions portfolio strengthens market position
- Long-term collaboration potential for future product offerings
Negative
- High monthly cost of $599 may limit market penetration
- Dependence on single supplier (Novo Nordisk) for key product
- No exclusivity mentioned in the partnership agreement
- Competitive pressure in increasingly crowded weight loss market
News Market Reaction – HIMS
On the day this news was published, HIMS gained 23.03%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Hims & Hers Partners with Novo Nordisk to Offer Wegovy® Treatment on Its Platform
Hims & Hers Health, Inc. (NYSE: HIMS) and Novo Nordisk announced on April 29, 2025, a long-term collaboration aimed at making obesity care and treatments more accessible and affordable for millions of Americans. The partnership begins with the immediate availability of Novo Nordisk's FDA-approved weight loss medication Wegovy® through the Hims & Hers platform.
According to the announcement, Americans can now access NovoCare® Pharmacy directly through the Hims & Hers platform, with a bundled offering that includes all dose strengths of Wegovy® alongside a Hims & Hers membership. The comprehensive package provides access to 24/7 care, ongoing clinical support, and nutrition guidance at a unified price starting at
The companies stated that this initial offering is available this week on the Hims & Hers platform. The collaboration represents the first step in what the companies describe as a longer-term partnership roadmap.
Strategic Vision
Andrew Dudum, CEO and founder of Hims & Hers, emphasized the significance of the partnership in the press release: "We're excited to work with Novo Nordisk, a company known for breakthrough innovation in clinical medicine and a strong portfolio of medications. We share a vision of what consumer-centered healthcare looks like, and this is just the first step towards delivering that future."
The partnership aligns with both companies' goals of expanding access to obesity treatment. Dave Moore, Executive Vice President, U.S. Operations and Global Business Development and President of Novo Nordisk Inc., noted: "We are pleased that Hims & Hers is making this offering available this week to people living with obesity. Beyond this initial collaboration, the companies are developing a roadmap that combines Novo Nordisk's innovative medications with Hims & Hers' ability to deliver access to quality care at scale."
Enhanced Weight Management Offerings
The press release indicated that this new offering builds upon Hims & Hers' existing suite of weight loss solutions. The company said it will continue to offer access to other medications, oral kits, protein, nutrition kits, and clinically-backed care plans on its platform.
According to the announcement, the bundled offering provides self-pay patients access to all dose strengths of Wegovy® in a high-quality pen format, giving patients more options to start and sustain their health journey based on their needs, goals, and eligibility.
The companies emphasized that their developing roadmap aims to improve long-term outcomes for more people living with chronic disease, potentially expanding beyond obesity care in the future. Both organizations expressed their shared commitment to delivering consumer-centered healthcare solutions.
This article is based solely on information provided in Hims & Hers Health, Inc.'s press release dated April 29, 2025. The content is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Stock Titan and its writers make no representations as to the accuracy, completeness, or timeliness of the information. Investors should conduct their own due diligence before making any investment decisions.
Source: Hims & Hers
FAQ
How much does Wegovy cost on Hims & Hers (NYSE: HIMS) platform in 2025?
What is included in the Novo Nordisk and Hims & Hers (HIMS) obesity care partnership?
Where can I buy Wegovy through Hims & Hers stock (HIMS) platform?
Will Hims & Hers (HIMS) stock benefit from the Novo Nordisk Wegovy partnership?
What weight loss medications does Hims & Hers (HIMS) offer in 2025?
